Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PRKD3 - Burkitt lymphoma subtypes: lymph-node biopsies
GEO DataSets Gene Profile neighbors Chromosome neighbors Homologene neighbors
PRKD3 - Saliva of pre-treatment pancreatic cancer patients
PRKD3 - 3-Deazaneplanocin A effect on multiple myeloma cells
PRKD3 - ERalpha-negative ERbeta-positive breast carcinoma response to tamoxifen
PRKD3 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
PRKD3 - Polybrominated diphenyl ethers effect on adrenocortical carcinoma cell line
PRKD3 - SW480 KRAS-mutant colorectal cancer cell line response to dual inhibition of tankyrase and MEK: time course
PRKD3 - Pristimerin effect on myeloma cell lines
PRKD3 - Adrenocortical adenomas harboring β-catenin gene CTNNB1 mutations
PRKD3 - Motexafin gadolinium and zinc effect on Ramos B-cell lymphoma line
PRKD3 - Leukotriene B4 effect on monocytes: time course
PRKD3 - Non-Hodgkin’s lymphoma cell lines response to antibodies against CD20 or B-cell receptor
PRKD3 - Telomere-elongated, prostate cancer cells
PRKD3 - Drug efflux transporter ABCB5 knockdown effect on G3361 melanoma cells
PRKD3 - Toll-like receptor agonists synergistic effect on dendritic cells: time course
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on